Dermatrends Announces Development Of Ground-breaking Transdermal NSAID Product
10/19/2005 5:13:10 PM
MINNEAPOLIS--(BUSINESS WIRE)--March 31, 2005--Dermatrends Inc. today announced that it has developed a transdermal nonsteroidal anti-inflammatory drug (NSAID) patch that combines its best-of-class transdermal technology with active ingredients such as meloxicam, which in oral form has been successfully used to treat such crippling conditions as osteoarthritis.
The Dermatrends' NSAID patch has been tested extensively in vitro, indicating that drugs such as meloxicam can be delivered to match systemic blood level concentrations currently delivered orally. A meloxicam patch of approximately 40 square centimeters (smaller than a standard business card) would be adequate to match the 15 mg /day oral dosage and patch size would decrease proportionately for lower dosages. In addition to meloxicam, the company has developed a similar transdermal patch utilizing diclofenac sodium.
comments powered by